Drug intelligence / Profile preview

NPH insulin + regular insulin + Lantus + Novolog + Humalog

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

This is a combination of five different insulin products used for diabetes management. It includes intermediate-acting NPH insulin, short-acting regular insulin, long-acting Lantus (insulin glargine), and rapid-acting Novolog (insulin aspart) and Humalog (insulin lispro). This combination provides both basal (background) insulin coverage and mealtime/bolus insulin coverage for blood glucose management.

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on NPH insulin + regular insulin + Lantus + Novolog + Humalog.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPH insulin + regular insulin + Lantus + Novolog + Humalog.

Explore the full profile